nodes	percent_of_prediction	percent_of_DWPC	metapath
Darunavir—Amprenavir—ABCB1—esophageal cancer	0.00411	1	CrCbGaD
Darunavir—Stomatitis—Cisplatin—esophageal cancer	0.00278	0.00279	CcSEcCtD
Darunavir—Hyponatraemia—Capecitabine—esophageal cancer	0.00274	0.00275	CcSEcCtD
Darunavir—Pain in extremity—Capecitabine—esophageal cancer	0.00273	0.00274	CcSEcCtD
Darunavir—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.0027	0.00272	CcSEcCtD
Darunavir—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0027	0.00271	CcSEcCtD
Darunavir—Bradycardia—Cisplatin—esophageal cancer	0.0026	0.00262	CcSEcCtD
Darunavir—Irritability—Capecitabine—esophageal cancer	0.0026	0.00261	CcSEcCtD
Darunavir—Mood swings—Capecitabine—esophageal cancer	0.00258	0.00259	CcSEcCtD
Darunavir—Blood creatinine increased—Capecitabine—esophageal cancer	0.00255	0.00256	CcSEcCtD
Darunavir—Urine output increased—Methotrexate—esophageal cancer	0.00253	0.00254	CcSEcCtD
Darunavir—Neoplasm—Methotrexate—esophageal cancer	0.00253	0.00254	CcSEcCtD
Darunavir—Urinary tract disorder—Cisplatin—esophageal cancer	0.00253	0.00254	CcSEcCtD
Darunavir—Liver function test abnormal—Capecitabine—esophageal cancer	0.00252	0.00253	CcSEcCtD
Darunavir—Connective tissue disorder—Cisplatin—esophageal cancer	0.00251	0.00252	CcSEcCtD
Darunavir—Urethral disorder—Cisplatin—esophageal cancer	0.00251	0.00252	CcSEcCtD
Darunavir—Gynaecomastia—Methotrexate—esophageal cancer	0.0025	0.00251	CcSEcCtD
Darunavir—Dry skin—Capecitabine—esophageal cancer	0.0025	0.00251	CcSEcCtD
Darunavir—Visual impairment—Cisplatin—esophageal cancer	0.00247	0.00248	CcSEcCtD
Darunavir—Breast disorder—Capecitabine—esophageal cancer	0.00246	0.00247	CcSEcCtD
Darunavir—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00245	0.00246	CcSEcCtD
Darunavir—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00245	0.00246	CcSEcCtD
Darunavir—Nasopharyngitis—Capecitabine—esophageal cancer	0.00244	0.00245	CcSEcCtD
Darunavir—Sepsis—Methotrexate—esophageal cancer	0.00243	0.00244	CcSEcCtD
Darunavir—Gastritis—Capecitabine—esophageal cancer	0.00241	0.00242	CcSEcCtD
Darunavir—Muscular weakness—Capecitabine—esophageal cancer	0.0024	0.00241	CcSEcCtD
Darunavir—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.0024	0.00241	CcSEcCtD
Darunavir—Eye disorder—Cisplatin—esophageal cancer	0.00239	0.0024	CcSEcCtD
Darunavir—Flushing—Cisplatin—esophageal cancer	0.00237	0.00238	CcSEcCtD
Darunavir—Cardiac disorder—Cisplatin—esophageal cancer	0.00237	0.00238	CcSEcCtD
Darunavir—Abdominal distension—Capecitabine—esophageal cancer	0.00237	0.00238	CcSEcCtD
Darunavir—Diabetes mellitus—Methotrexate—esophageal cancer	0.00233	0.00234	CcSEcCtD
Darunavir—Polyuria—Methotrexate—esophageal cancer	0.00231	0.00232	CcSEcCtD
Darunavir—Immune system disorder—Cisplatin—esophageal cancer	0.00231	0.00232	CcSEcCtD
Darunavir—Mediastinal disorder—Cisplatin—esophageal cancer	0.00231	0.00232	CcSEcCtD
Darunavir—Angina pectoris—Capecitabine—esophageal cancer	0.0023	0.0023	CcSEcCtD
Darunavir—Alopecia—Cisplatin—esophageal cancer	0.00226	0.00227	CcSEcCtD
Darunavir—Abdominal discomfort—Capecitabine—esophageal cancer	0.00226	0.00227	CcSEcCtD
Darunavir—Hepatic failure—Methotrexate—esophageal cancer	0.00226	0.00227	CcSEcCtD
Darunavir—Pancytopenia—Capecitabine—esophageal cancer	0.00224	0.00225	CcSEcCtD
Darunavir—Erythema—Cisplatin—esophageal cancer	0.00223	0.00224	CcSEcCtD
Darunavir—Malnutrition—Cisplatin—esophageal cancer	0.00223	0.00224	CcSEcCtD
Darunavir—Dysuria—Capecitabine—esophageal cancer	0.0022	0.00221	CcSEcCtD
Darunavir—Neutropenia—Capecitabine—esophageal cancer	0.0022	0.00221	CcSEcCtD
Darunavir—Renal failure acute—Methotrexate—esophageal cancer	0.0022	0.00221	CcSEcCtD
Darunavir—Flatulence—Cisplatin—esophageal cancer	0.00219	0.0022	CcSEcCtD
Darunavir—Weight increased—Capecitabine—esophageal cancer	0.00214	0.00215	CcSEcCtD
Darunavir—Visual disturbance—Methotrexate—esophageal cancer	0.00214	0.00215	CcSEcCtD
Darunavir—Muscle spasms—Cisplatin—esophageal cancer	0.00214	0.00215	CcSEcCtD
Darunavir—Weight decreased—Capecitabine—esophageal cancer	0.00213	0.00214	CcSEcCtD
Darunavir—Hyperglycaemia—Capecitabine—esophageal cancer	0.00213	0.00213	CcSEcCtD
Darunavir—Infestation NOS—Capecitabine—esophageal cancer	0.0021	0.00211	CcSEcCtD
Darunavir—Infestation—Capecitabine—esophageal cancer	0.0021	0.00211	CcSEcCtD
Darunavir—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00208	0.00209	CcSEcCtD
Darunavir—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00207	0.00208	CcSEcCtD
Darunavir—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00207	0.00208	CcSEcCtD
Darunavir—Lethargy—Methotrexate—esophageal cancer	0.00207	0.00208	CcSEcCtD
Darunavir—Ill-defined disorder—Cisplatin—esophageal cancer	0.00207	0.00207	CcSEcCtD
Darunavir—Renal failure—Capecitabine—esophageal cancer	0.00207	0.00207	CcSEcCtD
Darunavir—Myocardial infarction—Capecitabine—esophageal cancer	0.00206	0.00207	CcSEcCtD
Darunavir—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00206	0.00207	CcSEcCtD
Darunavir—Anaemia—Cisplatin—esophageal cancer	0.00206	0.00207	CcSEcCtD
Darunavir—Jaundice—Capecitabine—esophageal cancer	0.00205	0.00206	CcSEcCtD
Darunavir—Stomatitis—Capecitabine—esophageal cancer	0.00205	0.00206	CcSEcCtD
Darunavir—Malaise—Cisplatin—esophageal cancer	0.00201	0.00202	CcSEcCtD
Darunavir—Haematuria—Capecitabine—esophageal cancer	0.002	0.00201	CcSEcCtD
Darunavir—Leukopenia—Cisplatin—esophageal cancer	0.00199	0.002	CcSEcCtD
Darunavir—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00199	0.002	CcSEcCtD
Darunavir—Epistaxis—Capecitabine—esophageal cancer	0.00198	0.00199	CcSEcCtD
Darunavir—Irritability—Methotrexate—esophageal cancer	0.00194	0.00194	CcSEcCtD
Darunavir—Convulsion—Cisplatin—esophageal cancer	0.00193	0.00194	CcSEcCtD
Darunavir—Mood swings—Methotrexate—esophageal cancer	0.00192	0.00193	CcSEcCtD
Darunavir—Bradycardia—Capecitabine—esophageal cancer	0.00192	0.00193	CcSEcCtD
Darunavir—Myalgia—Cisplatin—esophageal cancer	0.0019	0.0019	CcSEcCtD
Darunavir—Haemoglobin—Capecitabine—esophageal cancer	0.0019	0.0019	CcSEcCtD
Darunavir—Anxiety—Cisplatin—esophageal cancer	0.00189	0.0019	CcSEcCtD
Darunavir—Haemorrhage—Capecitabine—esophageal cancer	0.00189	0.00189	CcSEcCtD
Darunavir—Hepatitis—Capecitabine—esophageal cancer	0.00189	0.00189	CcSEcCtD
Darunavir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00188	0.00189	CcSEcCtD
Darunavir—Hypoaesthesia—Capecitabine—esophageal cancer	0.00188	0.00188	CcSEcCtD
Darunavir—Liver function test abnormal—Methotrexate—esophageal cancer	0.00187	0.00188	CcSEcCtD
Darunavir—Discomfort—Cisplatin—esophageal cancer	0.00187	0.00188	CcSEcCtD
Darunavir—Urinary tract disorder—Capecitabine—esophageal cancer	0.00186	0.00187	CcSEcCtD
Darunavir—Oedema peripheral—Capecitabine—esophageal cancer	0.00186	0.00187	CcSEcCtD
Darunavir—Connective tissue disorder—Capecitabine—esophageal cancer	0.00185	0.00186	CcSEcCtD
Darunavir—Urethral disorder—Capecitabine—esophageal cancer	0.00185	0.00186	CcSEcCtD
Darunavir—Breast disorder—Methotrexate—esophageal cancer	0.00183	0.00184	CcSEcCtD
Darunavir—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00183	0.00183	CcSEcCtD
Darunavir—Visual impairment—Capecitabine—esophageal cancer	0.00182	0.00182	CcSEcCtD
Darunavir—Erythema multiforme—Capecitabine—esophageal cancer	0.00178	0.00179	CcSEcCtD
Darunavir—Nervous system disorder—Cisplatin—esophageal cancer	0.00178	0.00179	CcSEcCtD
Darunavir—Thrombocytopenia—Cisplatin—esophageal cancer	0.00178	0.00179	CcSEcCtD
Darunavir—Tachycardia—Cisplatin—esophageal cancer	0.00177	0.00178	CcSEcCtD
Darunavir—Skin disorder—Cisplatin—esophageal cancer	0.00177	0.00177	CcSEcCtD
Darunavir—Eye disorder—Capecitabine—esophageal cancer	0.00176	0.00177	CcSEcCtD
Darunavir—Hyperhidrosis—Cisplatin—esophageal cancer	0.00176	0.00176	CcSEcCtD
Darunavir—Flushing—Capecitabine—esophageal cancer	0.00175	0.00176	CcSEcCtD
Darunavir—Cardiac disorder—Capecitabine—esophageal cancer	0.00175	0.00176	CcSEcCtD
Darunavir—Eosinophilia—Methotrexate—esophageal cancer	0.00174	0.00174	CcSEcCtD
Darunavir—Anorexia—Cisplatin—esophageal cancer	0.00173	0.00174	CcSEcCtD
Darunavir—Pancreatitis—Methotrexate—esophageal cancer	0.00172	0.00173	CcSEcCtD
Darunavir—Angiopathy—Capecitabine—esophageal cancer	0.00171	0.00172	CcSEcCtD
Darunavir—Immune system disorder—Capecitabine—esophageal cancer	0.0017	0.00171	CcSEcCtD
Darunavir—Mediastinal disorder—Capecitabine—esophageal cancer	0.0017	0.00171	CcSEcCtD
Darunavir—Chills—Capecitabine—esophageal cancer	0.00169	0.0017	CcSEcCtD
Darunavir—Abdominal discomfort—Methotrexate—esophageal cancer	0.00168	0.00169	CcSEcCtD
Darunavir—Alopecia—Capecitabine—esophageal cancer	0.00167	0.00167	CcSEcCtD
Darunavir—Pancytopenia—Methotrexate—esophageal cancer	0.00167	0.00167	CcSEcCtD
Darunavir—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00166	0.00166	CcSEcCtD
Darunavir—Mental disorder—Capecitabine—esophageal cancer	0.00165	0.00166	CcSEcCtD
Darunavir—Erythema—Capecitabine—esophageal cancer	0.00164	0.00165	CcSEcCtD
Darunavir—Malnutrition—Capecitabine—esophageal cancer	0.00164	0.00165	CcSEcCtD
Darunavir—Dysuria—Methotrexate—esophageal cancer	0.00164	0.00165	CcSEcCtD
Darunavir—Neutropenia—Methotrexate—esophageal cancer	0.00164	0.00165	CcSEcCtD
Darunavir—Paraesthesia—Cisplatin—esophageal cancer	0.00163	0.00164	CcSEcCtD
Darunavir—Dyspnoea—Cisplatin—esophageal cancer	0.00162	0.00163	CcSEcCtD
Darunavir—Flatulence—Capecitabine—esophageal cancer	0.00162	0.00162	CcSEcCtD
Darunavir—Erectile dysfunction—Methotrexate—esophageal cancer	0.00162	0.00162	CcSEcCtD
Darunavir—Dysgeusia—Capecitabine—esophageal cancer	0.00161	0.00161	CcSEcCtD
Darunavir—Decreased appetite—Cisplatin—esophageal cancer	0.00158	0.00159	CcSEcCtD
Darunavir—Muscle spasms—Capecitabine—esophageal cancer	0.00158	0.00158	CcSEcCtD
Darunavir—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00157	0.00158	CcSEcCtD
Darunavir—Infestation NOS—Methotrexate—esophageal cancer	0.00156	0.00157	CcSEcCtD
Darunavir—Infestation—Methotrexate—esophageal cancer	0.00156	0.00157	CcSEcCtD
Darunavir—Pain—Cisplatin—esophageal cancer	0.00155	0.00156	CcSEcCtD
Darunavir—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00155	0.00156	CcSEcCtD
Darunavir—Renal failure—Methotrexate—esophageal cancer	0.00154	0.00154	CcSEcCtD
Darunavir—Stomatitis—Methotrexate—esophageal cancer	0.00152	0.00153	CcSEcCtD
Darunavir—Ill-defined disorder—Capecitabine—esophageal cancer	0.00152	0.00153	CcSEcCtD
Darunavir—Anaemia—Capecitabine—esophageal cancer	0.00152	0.00152	CcSEcCtD
Darunavir—Feeling abnormal—Cisplatin—esophageal cancer	0.0015	0.0015	CcSEcCtD
Darunavir—Haematuria—Methotrexate—esophageal cancer	0.00149	0.0015	CcSEcCtD
Darunavir—Malaise—Capecitabine—esophageal cancer	0.00148	0.00149	CcSEcCtD
Darunavir—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00148	0.00149	CcSEcCtD
Darunavir—Epistaxis—Methotrexate—esophageal cancer	0.00148	0.00148	CcSEcCtD
Darunavir—Vertigo—Capecitabine—esophageal cancer	0.00147	0.00148	CcSEcCtD
Darunavir—Syncope—Capecitabine—esophageal cancer	0.00147	0.00148	CcSEcCtD
Darunavir—Leukopenia—Capecitabine—esophageal cancer	0.00147	0.00148	CcSEcCtD
Darunavir—Palpitations—Capecitabine—esophageal cancer	0.00145	0.00146	CcSEcCtD
Darunavir—Loss of consciousness—Capecitabine—esophageal cancer	0.00144	0.00145	CcSEcCtD
Darunavir—Body temperature increased—Cisplatin—esophageal cancer	0.00144	0.00144	CcSEcCtD
Darunavir—Cough—Capecitabine—esophageal cancer	0.00143	0.00144	CcSEcCtD
Darunavir—Hypertension—Capecitabine—esophageal cancer	0.00142	0.00142	CcSEcCtD
Darunavir—Haemoglobin—Methotrexate—esophageal cancer	0.00141	0.00142	CcSEcCtD
Darunavir—Haemorrhage—Methotrexate—esophageal cancer	0.0014	0.00141	CcSEcCtD
Darunavir—Hepatitis—Methotrexate—esophageal cancer	0.0014	0.00141	CcSEcCtD
Darunavir—Myalgia—Capecitabine—esophageal cancer	0.0014	0.0014	CcSEcCtD
Darunavir—Arthralgia—Capecitabine—esophageal cancer	0.0014	0.0014	CcSEcCtD
Darunavir—Chest pain—Capecitabine—esophageal cancer	0.0014	0.0014	CcSEcCtD
Darunavir—Anxiety—Capecitabine—esophageal cancer	0.00139	0.0014	CcSEcCtD
Darunavir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00139	0.00139	CcSEcCtD
Darunavir—Urinary tract disorder—Methotrexate—esophageal cancer	0.00139	0.00139	CcSEcCtD
Darunavir—Discomfort—Capecitabine—esophageal cancer	0.00138	0.00139	CcSEcCtD
Darunavir—Urethral disorder—Methotrexate—esophageal cancer	0.00138	0.00138	CcSEcCtD
Darunavir—Dry mouth—Capecitabine—esophageal cancer	0.00137	0.00137	CcSEcCtD
Darunavir—Visual impairment—Methotrexate—esophageal cancer	0.00135	0.00136	CcSEcCtD
Darunavir—Confusional state—Capecitabine—esophageal cancer	0.00135	0.00136	CcSEcCtD
Darunavir—Hypersensitivity—Cisplatin—esophageal cancer	0.00134	0.00134	CcSEcCtD
Darunavir—Erythema multiforme—Methotrexate—esophageal cancer	0.00133	0.00133	CcSEcCtD
Darunavir—Shock—Capecitabine—esophageal cancer	0.00132	0.00132	CcSEcCtD
Darunavir—Nervous system disorder—Capecitabine—esophageal cancer	0.00131	0.00132	CcSEcCtD
Darunavir—Eye disorder—Methotrexate—esophageal cancer	0.00131	0.00132	CcSEcCtD
Darunavir—Thrombocytopenia—Capecitabine—esophageal cancer	0.00131	0.00132	CcSEcCtD
Darunavir—Tachycardia—Capecitabine—esophageal cancer	0.00131	0.00131	CcSEcCtD
Darunavir—Asthenia—Cisplatin—esophageal cancer	0.0013	0.00131	CcSEcCtD
Darunavir—Cardiac disorder—Methotrexate—esophageal cancer	0.0013	0.00131	CcSEcCtD
Darunavir—Skin disorder—Capecitabine—esophageal cancer	0.0013	0.00131	CcSEcCtD
Darunavir—Hyperhidrosis—Capecitabine—esophageal cancer	0.0013	0.0013	CcSEcCtD
Darunavir—Anorexia—Capecitabine—esophageal cancer	0.00128	0.00128	CcSEcCtD
Darunavir—Angiopathy—Methotrexate—esophageal cancer	0.00127	0.00128	CcSEcCtD
Darunavir—Immune system disorder—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Darunavir—Mediastinal disorder—Methotrexate—esophageal cancer	0.00127	0.00127	CcSEcCtD
Darunavir—Chills—Methotrexate—esophageal cancer	0.00126	0.00126	CcSEcCtD
Darunavir—Diarrhoea—Cisplatin—esophageal cancer	0.00124	0.00125	CcSEcCtD
Darunavir—Alopecia—Methotrexate—esophageal cancer	0.00124	0.00125	CcSEcCtD
Darunavir—Mental disorder—Methotrexate—esophageal cancer	0.00123	0.00124	CcSEcCtD
Darunavir—Malnutrition—Methotrexate—esophageal cancer	0.00122	0.00123	CcSEcCtD
Darunavir—Erythema—Methotrexate—esophageal cancer	0.00122	0.00123	CcSEcCtD
Darunavir—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00122	0.00123	CcSEcCtD
Darunavir—Insomnia—Capecitabine—esophageal cancer	0.00121	0.00122	CcSEcCtD
Darunavir—Paraesthesia—Capecitabine—esophageal cancer	0.0012	0.00121	CcSEcCtD
Darunavir—Dysgeusia—Methotrexate—esophageal cancer	0.0012	0.0012	CcSEcCtD
Darunavir—Dyspnoea—Capecitabine—esophageal cancer	0.00119	0.0012	CcSEcCtD
Darunavir—Dyspepsia—Capecitabine—esophageal cancer	0.00118	0.00118	CcSEcCtD
Darunavir—Decreased appetite—Capecitabine—esophageal cancer	0.00116	0.00117	CcSEcCtD
Darunavir—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00116	0.00116	CcSEcCtD
Darunavir—Vomiting—Cisplatin—esophageal cancer	0.00116	0.00116	CcSEcCtD
Darunavir—Fatigue—Capecitabine—esophageal cancer	0.00116	0.00116	CcSEcCtD
Darunavir—Rash—Cisplatin—esophageal cancer	0.00115	0.00115	CcSEcCtD
Darunavir—Pain—Capecitabine—esophageal cancer	0.00115	0.00115	CcSEcCtD
Darunavir—Constipation—Capecitabine—esophageal cancer	0.00115	0.00115	CcSEcCtD
Darunavir—Dermatitis—Cisplatin—esophageal cancer	0.00115	0.00115	CcSEcCtD
Darunavir—Ill-defined disorder—Methotrexate—esophageal cancer	0.00113	0.00114	CcSEcCtD
Darunavir—Anaemia—Methotrexate—esophageal cancer	0.00113	0.00113	CcSEcCtD
Darunavir—Feeling abnormal—Capecitabine—esophageal cancer	0.0011	0.00111	CcSEcCtD
Darunavir—Malaise—Methotrexate—esophageal cancer	0.0011	0.00111	CcSEcCtD
Darunavir—Vertigo—Methotrexate—esophageal cancer	0.0011	0.0011	CcSEcCtD
Darunavir—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0011	0.0011	CcSEcCtD
Darunavir—Leukopenia—Methotrexate—esophageal cancer	0.00109	0.0011	CcSEcCtD
Darunavir—Nausea—Cisplatin—esophageal cancer	0.00108	0.00108	CcSEcCtD
Darunavir—Cough—Methotrexate—esophageal cancer	0.00107	0.00107	CcSEcCtD
Darunavir—Urticaria—Capecitabine—esophageal cancer	0.00106	0.00107	CcSEcCtD
Darunavir—Abdominal pain—Capecitabine—esophageal cancer	0.00106	0.00106	CcSEcCtD
Darunavir—Body temperature increased—Capecitabine—esophageal cancer	0.00106	0.00106	CcSEcCtD
Darunavir—Convulsion—Methotrexate—esophageal cancer	0.00106	0.00106	CcSEcCtD
Darunavir—Arthralgia—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Darunavir—Myalgia—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Darunavir—Chest pain—Methotrexate—esophageal cancer	0.00104	0.00104	CcSEcCtD
Darunavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00103	0.00104	CcSEcCtD
Darunavir—Discomfort—Methotrexate—esophageal cancer	0.00103	0.00103	CcSEcCtD
Darunavir—Confusional state—Methotrexate—esophageal cancer	0.00101	0.00101	CcSEcCtD
Darunavir—Hypersensitivity—Capecitabine—esophageal cancer	0.000987	0.000991	CcSEcCtD
Darunavir—Nervous system disorder—Methotrexate—esophageal cancer	0.000978	0.000982	CcSEcCtD
Darunavir—Thrombocytopenia—Methotrexate—esophageal cancer	0.000977	0.000981	CcSEcCtD
Darunavir—Skin disorder—Methotrexate—esophageal cancer	0.000969	0.000973	CcSEcCtD
Darunavir—Hyperhidrosis—Methotrexate—esophageal cancer	0.000964	0.000968	CcSEcCtD
Darunavir—Asthenia—Capecitabine—esophageal cancer	0.000961	0.000965	CcSEcCtD
Darunavir—Anorexia—Methotrexate—esophageal cancer	0.000951	0.000955	CcSEcCtD
Darunavir—Pruritus—Capecitabine—esophageal cancer	0.000948	0.000952	CcSEcCtD
Darunavir—Diarrhoea—Capecitabine—esophageal cancer	0.000917	0.000921	CcSEcCtD
Darunavir—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000909	0.000912	CcSEcCtD
Darunavir—Insomnia—Methotrexate—esophageal cancer	0.000902	0.000906	CcSEcCtD
Darunavir—Paraesthesia—Methotrexate—esophageal cancer	0.000896	0.000899	CcSEcCtD
Darunavir—Dyspnoea—Methotrexate—esophageal cancer	0.000889	0.000893	CcSEcCtD
Darunavir—Somnolence—Methotrexate—esophageal cancer	0.000887	0.00089	CcSEcCtD
Darunavir—Dizziness—Capecitabine—esophageal cancer	0.000886	0.00089	CcSEcCtD
Darunavir—Dyspepsia—Methotrexate—esophageal cancer	0.000878	0.000882	CcSEcCtD
Darunavir—Decreased appetite—Methotrexate—esophageal cancer	0.000867	0.000871	CcSEcCtD
Darunavir—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000861	0.000865	CcSEcCtD
Darunavir—Fatigue—Methotrexate—esophageal cancer	0.00086	0.000863	CcSEcCtD
Darunavir—Pain—Methotrexate—esophageal cancer	0.000853	0.000856	CcSEcCtD
Darunavir—Vomiting—Capecitabine—esophageal cancer	0.000852	0.000855	CcSEcCtD
Darunavir—Rash—Capecitabine—esophageal cancer	0.000845	0.000848	CcSEcCtD
Darunavir—Dermatitis—Capecitabine—esophageal cancer	0.000844	0.000848	CcSEcCtD
Darunavir—Headache—Capecitabine—esophageal cancer	0.000839	0.000843	CcSEcCtD
Darunavir—Feeling abnormal—Methotrexate—esophageal cancer	0.000822	0.000825	CcSEcCtD
Darunavir—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000816	0.000819	CcSEcCtD
Darunavir—Nausea—Capecitabine—esophageal cancer	0.000796	0.000799	CcSEcCtD
Darunavir—Urticaria—Methotrexate—esophageal cancer	0.000792	0.000796	CcSEcCtD
Darunavir—Body temperature increased—Methotrexate—esophageal cancer	0.000788	0.000792	CcSEcCtD
Darunavir—Abdominal pain—Methotrexate—esophageal cancer	0.000788	0.000792	CcSEcCtD
Darunavir—Hypersensitivity—Methotrexate—esophageal cancer	0.000735	0.000738	CcSEcCtD
Darunavir—Asthenia—Methotrexate—esophageal cancer	0.000716	0.000719	CcSEcCtD
Darunavir—Pruritus—Methotrexate—esophageal cancer	0.000706	0.000709	CcSEcCtD
Darunavir—Diarrhoea—Methotrexate—esophageal cancer	0.000682	0.000685	CcSEcCtD
Darunavir—Dizziness—Methotrexate—esophageal cancer	0.00066	0.000662	CcSEcCtD
Darunavir—Vomiting—Methotrexate—esophageal cancer	0.000634	0.000637	CcSEcCtD
Darunavir—Rash—Methotrexate—esophageal cancer	0.000629	0.000631	CcSEcCtD
Darunavir—Dermatitis—Methotrexate—esophageal cancer	0.000628	0.000631	CcSEcCtD
Darunavir—Headache—Methotrexate—esophageal cancer	0.000625	0.000627	CcSEcCtD
Darunavir—Nausea—Methotrexate—esophageal cancer	0.000592	0.000595	CcSEcCtD
